1 November 2020 - The November 2020 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The November issue of the Schedule includes a few new/revised listings:

• Atezolizumab (Tecentriq) - new indication
• Bevacizumab (Avastin) - new indication
• Glycomacropeptide with essential amino acids and vitamins and minerals (Tylactin Build 20) - new formulation
  
• Methoxsalen (Uvadex) - new medicine
• Olaparib (Lynparza) - new indication
• Siponimod hemifumarate (Mayzent) - new medicine
• Topotecan (Topotecan Accord) - new formulation

Read Summary of PBS changes